J. Neal

H. Stehr, J. Neal, H. Wakelee, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

J. Neal, M. Shah, 2022, Drugs.

O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

J. Neal, H. Wakelee, L. Sequist, 2015 .

Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.

K. Ramchandran, E. Rosenthal, J. Neal, 2021, JCO oncology practice.

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

P62.03 Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening

Summer S. Han, A. Leung, J. Neal, 2021, Journal of Thoracic Oncology.

Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms

G. Davidzon, E. Mittra, A. Iagaru, 2012 .

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

L. Schwartz, R. Govindan, J. Neal, 2022, Journal for ImmunoTherapy of Cancer.

Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.

N. Myall, H. Stehr, J. Neal, 2016, Clinical lung cancer.

Emerging treatments for small-cell lung cancer: Phase II and III trials

J. Neal, H. Wakelee, M. Gubens, 2011 .

Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study

Y. Hu, J. Neal, Xiaolong Yan, 2022, Translational lung cancer research.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

M. Kris, V. Rusch, C. Azzoli, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase – Positive Non – Small-Cell Lung Cancer

J. Neal, H. Wakelee, 2017 .

Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.

J. Neal, H. Wakelee, D. Wood, 2017, JCO clinical cancer informatics.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.

Julian C. Hong, J. Neal, H. Wakelee, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer

J. Neal, H. Wakelee, Ying-ying Liang, 2014, Clinical lung cancer.

Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.

J. Neal, H. Wakelee, D. Ho, 2020, Clinical lung cancer.

The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer

Summer S. Han, L. Le Marchand, L. Wilkens, 2021, Journal of the National Cancer Institute.

Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases

Steven D Chang, K. Ramchandran, S. Hancock, 2021, Journal of Neuro-Oncology.

Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

J. Neal, H. Wakelee, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Dermatologic Complications of Lung Cancer Therapies

J. Neal, B. Kwong, S. Pugliese, 2015, Current Treatment Options in Oncology.

Aflibercept in lung cancer

J. Neal, H. Wakelee, 2013, Expert opinion on biological therapy.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.

J. Neal, L. Sequist, 2013, Translational lung cancer research.

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.

J. Neal, J. Riess, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

J. Neal, J. Riess, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.

J. Neal, H. Wakelee, L. Sequist, 2013 .

Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells.

D. G. Zisoulis, J. Neal, G. Kansas, 2003, Blood.

Pruritus as a Paraneoplastic Symptom of Thymoma.

J. Shrager, J. Neal, H. Wakelee, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rapid Hydroxychloroquine Toxicity in Cancer Therapy

J. Neal, H. Wakelee, L. Sequist, 2015 .

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.

M. Marmor, J. Neal, H. Wakelee, 2015, American journal of ophthalmology.

Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data

Ruishan Liu, J. Neal, C. Harbron, 2022, Nature Medicine.

Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors

J. Neal, H. Wakelee, S. Srinivas, 2021, JACC. CardioOncology.

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.

Mark M. Davis, J. Neal, P. Nguyen, 2020, Annual review of pharmacology and toxicology.

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

C. Azzoli, P. Jänne, R. Govindan, 2012 .

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

J. Neal, E. Felip, R. Gentzler, 2020 .

Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.

J. Neal, H. Wakelee, J. Hellyer, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

M. Erlander, J. Neal, H. Wakelee, 2016 .

PET/CT in lung cancer Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer Radiotherapy and Oncology

Julian C. Hong, J. Neal, H. Wakelee, 2018 .

CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

J. Neal, N. Pavlakis, P. Kundu, 2021 .

Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.

K. Ramchandran, N. Myall, J. Neal, 2022, Clinical lung cancer.

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer

J. Neal, Yuanlin Song, Xinjun Tang, 2021, Translational lung cancer research.

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis

J. Neal, H. Wakelee, P. Nguyen, 2022, Circulation.

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

J. Neal, S. Ou, Jianchang Lin, 2021 .

Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.

J. Neal, A. Cheng, A. Vogel, 2022, Cancer treatment reviews.

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer

J. Neal, Tim J Ellis-Caleo, Tim Ellis-Caleo, 2021, Journal of thoracic disease.

Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes

Hanlee P. Ji, Summer S. Han, N. Myall, 2022, JCO precision oncology.

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.

J. Neal, H. Wakelee, 2010, Current opinion in molecular therapeutics.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

M. Kris, C. Azzoli, P. Jänne, 2014 .

Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA).

R. West, L. Tian, Y. Natkunam, 2014 .

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.

A. Chaudhuri, J. Neal, H. Wakelee, 2022, Cancer treatment and research communications.

Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer

K. Ramchandran, N. Myall, J. Neal, 2022, Journal of Neuro-Oncology.

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.

J. Neal, Shufeng Li, B. Kwong, 2019, JAMA dermatology.

Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors

Chuong D. Hoang, L. Tian, A. Leung, 2017, Journal of thoracic imaging.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.

Alexander X. Lozano, S. Gambhir, J. Neal, 2021, Clinical chemistry.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Maximilian Diehn, Aaron M. Newman, 2016, Nature Communications.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

J. Neal, Jianchang Lin, L. Horn, 2020 .

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

J. Neal, L. Sequist, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer

K. Ramchandran, H. Stehr, J. Neal, 2019, Clinical Cancer Research.

Calcineurin Mediates the Calcium-dependent Inhibition of Adipocyte Differentiation in 3T3-L1 Cells*

J. Neal, N. Clipstone, 2002, The Journal of Biological Chemistry.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Ash A. Alizadeh, Aaron M. Newman, A. Newman, 2020, Cell.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Ash A. Alizadeh, Aaron M. Newman, R. West, 2017, Cancer Discovery.

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Clinical lung cancer.

Molecular profiling of single circulating tumor cells from lung cancer patients

Amin Aalipour, Ophir Vermesh, Sanjiv S Gambhir, 2016, Proceedings of the National Academy of Sciences.

KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.

Ash A. Alizadeh, K. Ramchandran, J. Shrager, 2020, Cancer discovery.

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Ash A. Alizadeh, K. Ramchandran, J. Chabon, 2020, Nature Cancer.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

K. Ramchandran, H. Stehr, J. Neal, 2019, Lung cancer.

Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.

J. Shrager, J. Neal, C. Kunder, 2018, Lung cancer.

Radiological tumor classification across imaging modality and histology

Carola-Bibiane Schönlieb, Ruijiang Li, Hiroki Shirato, 2021, Nature Machine Intelligence.

GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.

R. West, C. Hoang, J. Neal, 2015, Anticancer research.

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

R. West, L. Tian, H. Kohrt, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current management of small cell lung cancer.

J. Neal, H. Wakelee, M. Gubens, 2011, Clinics in chest medicine.

OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

J. Neal, R. Herbst, F. Hirsch, 2021 .

Targeted therapies: Optimal first-line therapy for NSCLC with EGFR mutations

J. Neal, L. Sequist, 2010, Nature Reviews Clinical Oncology.

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

J. Neal, L. Sequist, 2010, Clinical advances in hematology & oncology : H&O.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

R. West, J. Neal, H. Wakelee, 2015, Lung cancer.

Increased Galectin-1 Expression in Thymic Epithelial Tumors.

R. West, J. Neal, H. Wakelee, 2019, Clinical lung cancer.

MET inhibitors in combination with other therapies in non-small cell lung cancer.

J. Neal, H. Wakelee, S. Padda, 2012, Translational lung cancer research.

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.

J. Neal, N. Lindeman, P. Cagle, 2014, Archives of pathology & laboratory medicine.

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer

J. Neal, 2010, The oncologist.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.

Summer S. Han, J. Shrager, J. Neal, 2019, Lung cancer.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Aaron M. Newman, Kathleen A. Durkin, 2016, Nature Communications.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

J. Neal, T. Lynch, I. Bondarenko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

S. Digumarthy, J. Neal, L. Sequist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel systemic therapy against malignant pleural mesothelioma.

J. Neal, Michael R. Mancuso, M. Mancuso, 2017, Translational lung cancer research.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

Decade in review—targeted therapy: Successes, toxicities and challenges in solid tumours

George W. Sledge, Joel W. Neal, G. Sledge, 2014, Nature Reviews Clinical Oncology.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Marek Ancukiewicz, Thomas J Lynch, Rakesh K Jain, 2015, Proceedings of the National Academy of Sciences.

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Ash A. Alizadeh, Daniel K. Wells, C. Liu, 2020, Clinical Cancer Research.

Dermatologic complications of traditional cytotoxic therapies for lung cancer

J. Neal, B. Kwong, S. Pugliese, 2015 .

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.

Chin Chun Ooi, Irving L Weissman, Richard S Gaster, 2014, Lab on a chip.

Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer

J. Neal, H. Wakelee, T. Abbasi, 2021, JCO precision oncology.

Review of the current targeted therapies for non-small-cell lung cancer.

J. Neal, H. Wakelee, K. Nguyen, 2014, World journal of clinical oncology.

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

J. Neal, K. Nguyen, 2012, Biologics : targets & therapy.

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.

J. Neal, H. Wakelee, J. Riess, 2013, Clinical lung cancer.

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

J. Neal, H. Wakelee, D. Carbone, 2016, The Lancet. Oncology.

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

J. Neal, L. Sequist, 2010, Current treatment options in oncology.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer

Helio A. Costa, C. Bustamante, J. Neal, 2017, Molecular Diagnosis & Therapy.

Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.

J. Neal, H. Wakelee, J. Aredo, 2021, Cancer treatment and research communications.

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

J. Neal, H. Wakelee, J. Kawashima, 2021, Cancer Chemotherapy and Pharmacology.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.

Summer S. Han, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.

K. Ramchandran, J. Neal, H. Wakelee, 2019, Lung cancer.

The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

J. Neal, Jody C. Chuang, 2017, Cancer.

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.

J. Neal, H. Wakelee, Jody C. Chuang, 2015, Lung cancer.

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.

K. Ramchandran, J. Neal, H. Wakelee, 2014, Clinical lung cancer.

A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.

J. Neal, H. Wakelee, J. Riess, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

S. Digumarthy, J. Neal, H. Wakelee, 2023, JTO clinical and research reports.

Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

J. Neal, L. Sequist, P. Fidias, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam

H. Stehr, J. Neal, H. Wakelee, 2018, Journal of global oncology.

Developing biomarker-specific end points in lung cancer clinical trials

J. Neal, A. Shaw, J. Gainor, 2015, Nature Reviews Clinical Oncology.

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

R. Mak, J. Neal, L. Sequist, 2011, The oncologist.

Abstract 4610: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

A. Butte, J. Dudley, P. Khatri, 2014 .

Natural Disease History, Outcomes, and Co‐mutations in a Series of Patients With BRAF‐Mutated Non–small‐cell Lung Cancer

Summer S. Han, N. Myall, J. Neal, 2019, Clinical lung cancer.

A Constitutively Active NFATc1 Mutant Induces a Transformed Phenotype in 3T3-L1 Fibroblasts*

J. Neal, N. Clipstone, 2003, The Journal of Biological Chemistry.

The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%

J. Neal, Arpeet T. Shah, 2021 .

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib

J. Neal, H. Wakelee, C. Kunder, 2019, Anti-cancer drugs.

Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer

Jennifer L. Caswell-Jin, N. Myall, J. Neal, 2023, JACC. CardioOncology.

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Mark M. Davis, P. A. Futreal, I. Weissman, 2021, Immunity.

Glycogen Synthase Kinase-3 Inhibits the DNA Binding Activity of NFATc*

J. Neal, N. Clipstone, 2001, The Journal of Biological Chemistry.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.

L. Hofmann, J. Neal, Arpeet T. Shah, 2016, Journal of oncology practice.

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.

Steven D Chang, J. Adler, J. Neal, 2015, International journal of radiation oncology, biology, physics.

Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.

K. Ramchandran, N. Myall, J. Neal, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

J. Neal, Jody C. Chuang, 2015, Translational lung cancer research.

Relationship between anti-depressant use and lung cancer survival.

E. Bowman, J. Neal, J. Sage, 2017, Cancer treatment and research communications.

Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging

K. Ramchandran, R. Ko, J. Neal, 2023, Frontiers in Oncology.

Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

J. Neal, H. Wakelee, S. Soltys, 2018, The oncologist.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

J. Neal, H. Wakelee, L. Sequist, 2021, Clinical lung cancer.

Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.

J. Neal, H. Wakelee, J. Riess, 2015, Lung cancer.

Dissecting metastasis using preclinical models and methods

J. Neal, M. Winslow, Jess D. Hebert, 2023, Nature Reviews Cancer.

Prognostic Value of Pretreatment FDG‐PET Parameters in High‐dose Image‐guided Radiotherapy for Oligometastatic Non–Small‐cell Lung Cancer

J. Neal, H. Wakelee, B. Loo, 2018, Clinical lung cancer.

Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.

J. Neal, H. Wakelee, A. Chakraborty, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".

Summer S. Han, J. Shrager, J. Neal, 2019, Lung cancer.

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

P. Jänne, J. Neal, Gregory Riely, 2019, Annals of Oncology.

Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

J. Shrager, J. Neal, H. Wakelee, 2016, Clinical therapeutics.

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

B. Taylor, J. Neal, W. El-Deiry, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.

J. Neal, H. Wakelee, K. P. Raj, 2020, Clinical lung cancer.

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Joe Y. Chang, Sheeba J. Sujit, J. Hazle, 2023, The Lancet. Digital health.

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib

J. Neal, H. Wakelee, C. Liang, 2019, Journal of Thoracic Oncology.

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

J. Neal, E. Felip, A. Santoro, 2022, Journal of Clinical Oncology.

Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC

Ash A. Alizadeh, A. Newman, J. Shrager, 2014 .

Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing

Ash A. Alizadeh, A. Newman, J. Shrager, 2013 .

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

J. Neal, H. Wakelee, J. Riess, 2020, Journal of Clinical Oncology.

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials

P. Jänne, J. Neal, D. Costa, 2017 .

141P Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib

K. Ramchandran, J. Neal, H. Wakelee, 2021 .

Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).

K. Ramchandran, J. Neal, H. Wakelee, 2015 .

A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.

J. Neal, H. Wakelee, J. Sage, 2020, Cancer treatment and research communications.

A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

C. Azzoli, P. Jänne, J. Neal, 2010 .

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

J. Neal, H. Wakelee, A. Razak, 2012, British Journal of Cancer.

Unicentric, multifocal Castleman disease of the mediastinum associated with cerebellitis.

J. Neal, B. Burt, M. Hamaji, 2015, The Annals of thoracic surgery.

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.

M. van de Rijn, Y. Natkunam, J. Neal, 2023, JTO clinical and research reports.

Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer

N. Shah, K. Ramchandran, N. Myall, 2022, JCO oncology practice.

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab with and without Atezolizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

M. Socinski, J. Neal, H. Wakelee, 2023, Clinical Lung Cancer.

PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR‐102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology

J. Neal, H. Wakelee, S. Soltys, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P2.03b-012 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Brain Meta

J. Neal, H. Wakelee, S. Soltys, 2016 .

Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.

N. Myall, J. Neal, H. Wakelee, 2022, International Journal of Radiation Oncology, Biology, Physics.

Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.

J. Neal, Jeffrey Zweig, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer

K. Ramchandran, Robert W. Hsieh, J. Neal, 2021, Journal of Patient-Reported Outcomes.

MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients

J. Neal, H. Wakelee, J. Nieva, 2017 .

88OCNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts)

J. Neal, H. Wakelee, S. Patel, 2017 .

P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK

J. Neal, H. Wakelee, C. Liang, 2016 .

Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?

B. Taylor, J. Neal, W. El-Deiry, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

J. Neal, Gregory Riely, D. Costa, 2019, Journal of Clinical Oncology.

Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.

J. Neal, H. Wakelee, M. Diehn, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.

Ash A. Alizadeh, Aaron M. Newman, A. Newman, 2017 .

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.

J. Neal, 2010, Future oncology.

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity

J. Neal, P. Nguyen, Sean M. Wu, 2022, JACC. CardioOncology.

Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

J. Neal, H. Wakelee, C. Liang, 2016 .

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.

A. Sung, J. Neal, T. Sun, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report

J. Neal, L. Brčić, Cheng Chen, 2022, Annals of Translational Medicine.

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

P. Jänne, J. Neal, Gregory Riely, 2020 .

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

P. Jänne, J. Neal, Gregory Riely, 2018, Journal of Thoracic Oncology.

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study

J. Neal, Yu Dong, Xueyan Zhang, 2022, Translational lung cancer research.

Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.

J. Neal, S. Ou, Jianchang Lin, 2023, Lung cancer.

Abstract 5666: A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer

Ash A. Alizadeh, Aaron M. Newman, K. Ramchandran, 2020, Tumor Biology.

A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.

Ash A. Alizadeh, K. Ramchandran, J. Chabon, 2020 .

Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes

Ash A. Alizadeh, K. Ramchandran, J. Chabon, 2019, International Journal of Radiation Oncology, Biology, Physics.

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.

A. Mansfield, J. Neal, R. Heist, 2023, Clinical lung cancer.

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Duc Minh Nguyen, P. Jänne, J. Neal, 2021, Journal of Thoracic Oncology.

Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer.

K. Ramchandran, J. Neal, S. Srinivas, 2021, Journal of Clinical Oncology.

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.

J. Neal, H. Wakelee, L. Sequist, 2019, Journal of Clinical Oncology.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Ash A. Alizadeh, Aaron M. Newman, Justin N. Carter, 2017, Cancer discovery.

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

J. Neal, H. Wakelee, R. Herbst, 2023, Journal of Clinical Oncology.

Regulation of the glucose:H+ symporter by metabolite-activated ATP-dependent phosphorylation of HPr in Lactobacillus brevis

J. W. Neal, J. Neal, M. Saier, 1994, Journal of bacteriology.

The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

J. Neal, Jody C. Chuang, 2017, Cancer.

Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry

J. Neal, J. Benson, S. Bendall, 2023, Scientific reports.